Lehrstuhl für Innere Medizin IV

Renal denervation Really an alternative to reducing blood pressure? (2022) Striepe K, Schiffer M, Schmieder R Journal article Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers (2022) Geßner A, Gemeinhardt A, Bosch A, Kannenkeril D, Staerk C, Mayr A, Fromm M, et al. Journal article NT-proBNP and stem cell factor plasma concentrations are independently associated with cardiovascular outcomes in end-stage renal disease hemodialysis patients. (2022) Rossignol P, Duarte K, Bresso E, Åsberg A, Devignes MD, Eriksson N, Girerd N, et al. Journal article The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial (2022) Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, Ott C, et al. Journal article Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial (2022) Kario K, Mahfoud F, Kandzari DE, Townsend RR, Weber MA, Schmieder R, Tsioufis K, et al. Journal article The Effect of Filter Lifespan during Continuous Renal Replacement Therapy in Critically Ill Patients with Acute Kidney Injury on the Rate of New-Onset Infection: Analysis from the RICH Randomized Controlled Trial. (2022) Gerss J, Meersch M, Kindgen-Milles D, Brandenburger T, Willam C, Kellum JA, Zarbock A Journal article Midkine Promotes Metastasis and Therapeutic Resistance via mTOR/RPS6 in Uveal Melanoma. (2022) Karg M, John L, Refaian N, Büttner C, Rottmar T, Sommer J, Bock B, et al. Journal article Loss of Polycystin-1 causes cAMP-dependent switch from tubule to cyst formation. (2022) Scholz J, Kraus A, Lueder D, Skoczynski K, Schiffer M, Grampp S, Schödel J, Buchholz B Journal article Diverse molecular causes of unsolved autosomal dominant tubulointerstitial kidney diseases (2022) Wopperer F, Knaup K, Stanzick KJ, Schneider K, Jobst-Schwan T, Ekici AB, Uebe S, et al. Journal article Monitoring complement biomarkers in C3 glomerulopathy patients with factor H or FHR gene mutations before and after treatment with eculizumab or ravulizumab (2022) Vanderliek K, Afonso S, Loeschmann I, Krebs C, Wiech T, Skerka C, Zipfel P, Wiesener M Conference contribution